Journal
EMBO MOLECULAR MEDICINE
Volume 10, Issue 11, Pages -Publisher
WILEY
DOI: 10.15252/emmm.201708799
Keywords
autophagy; lysosomal biogenesis; mitochondrial disease; mTORC1; rapamycin
Categories
Funding
- MRC [MC_UU_00015/5]
- ERC [FP7-322424]
- NRJ-Institut de France Grant
- MRC [MC_UU_00015/8, MC_UU_00015/5] Funding Source: UKRI
Ask authors/readers for more resources
The mTOR inhibitor rapamycin ameliorates the clinical and biochemical phenotype of mouse, worm, and cellular models of mitochondrial disease, via an unclear mechanism. Here, we show that prolonged rapamycin treatment improved motor endurance, corrected morphological abnormalities of muscle, and increased cytochrome c oxidase (COX) activity of a muscle-specific Cox15 knockout mouse (Cox15(sm/sm)). Rapamycin treatment restored autophagic flux, which was impaired in naive Cox15(sm/sm) muscle, and reduced the number of damaged mitochondria, which accumulated in untreated Cox15(sm/sm) mice. Conversely, rilmenidine, an mTORC1-independent autophagy inducer, was ineffective on the myopathic features of Cox15(sm/sm) animals. This stark difference supports the idea that inhibition of mTORC1 by rapamycin has a key role in the improvement of the mitochondrial function in Cox15(sm/sm) muscle. In contrast to rilmenidine, rapamycin treatment also activated lysosomal biogenesis in muscle. This effect was associated with increased nuclear localization of TFEB, a master regulator of lysosomal biogenesis, which is inhibited by mTORC1-dependent phosphorylation. We propose that the coordinated activation of autophagic flux and lysosomal biogenesis contribute to the effective clearance of dysfunctional mitochondria by rapamycin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available